
Cereno Scientific is pioneering treatments to enhance and extend life. The innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Cereno Scientific is advancing a pipeline that includes an HDACi portfolio with two drug candidates in clinical phase – CS1 in pulmonary arterial hypertension (PAH) and CS014 in idiopathic pulmonary fibrosis (IPF). The HDACi portfolio has an innovative disease-modifying approach to addressing the root mechanism of rare and fatal diseases, untapping the…
Annual Revenue$10M to $25M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.